S3844: Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
S3844 is a HCPCS Level II code for dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness. It belongs to the Temporary National Codes (Non-Medicare) section. Medicare does not pay it: see the coverage note below before you bill it.
Medicare coverage: Not payable by Medicare
Medicare does not pay this code. It may still be valid for another payer, but a Medicare claim carrying it will not be reimbursed.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusI
Not valid for Medicare purposes. Medicare uses another code.
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for S3844
- Long descriptor
- Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness
- Short descriptor
- Dna analysis deafness
- Added
- July 1, 2003
- BETOS
- Z2
- Pricing indicator
- 00: Not priced by Part B
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Service not separately priced by Part B, not covered, bundled into another service, or used by Part A only.
Codes adjacent to S3844
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If S3844 is not quite right, the correct code is very often within a few positions of it.
- S3655Antisperm antibodies test (immunobead)
- S3708Gastrointestinal fat absorption study
- S3721Prostate cancer antigen 3 (pca3) testingterminated
- S3722Dose optimization by area under the curve (auc) analysis, for infusional 5-fluorouracil
- S3800Genetic testing for amyotrophic lateral sclerosis (als)
- S3840Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2
- S3841Genetic testing for retinoblastoma
- S3842Genetic testing for von hippel-lindau disease
- S3845Genetic testing for alpha-thalassemia
- S3846Genetic testing for hemoglobin e beta-thalassemia
- S3849Genetic testing for niemann-pick disease
- S3850Genetic testing for sickle cell anemia
- S3852Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease
- S3853Genetic testing for myotonic muscular dystrophy
- S3854Gene expression profiling panel for use in the management of breast cancer treatment
- S3855Genetic testing for detection of mutations in the presenilin - 1 geneterminated